Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Pfizer Stops GLP-1 Obesity Trial Because of High Discontinuation Rates.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
The article focuses on Pfizer's decision to halt a phase 2 trial of the twice-daily oral glucagon-like peptide-1 receptor agonist (GLP-1) danuglipron for treating obesity, citing a higher discontinuation rate among patients despite meeting the primary endpoint. It mentions Pfizer is now shifting focus to a pharmacokinetic study for a once-daily formulation of danuglipron.
No Comments.